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Introduction {#sec1}
============

A large proportion of the human kinome requires chaperoning through the Hsp90 pathway to be activated and/or assembled into functional complexes. Protein kinases are recognized and bound by Cdc37, which acts as a gatekeeper to direct this particular class of client proteins to Hsp90 ([@bib31]). Molecular details of how Cdc37 recognizes diverse protein kinase sequences have been elucidated recently by determination of a structure of an Hsp90-Cdc37-CDK4 complex by cryoelectron microscopy ([@bib47]). This structure confirms earlier studies that implicated sequence features of the protein kinase N-terminal lobe and ATP-binding cleft as contributing to the Cdc37 binding site ([@bib11], [@bib12], [@bib30], [@bib48], [@bib50]). Cdc37-Hsp90 associates with client kinases both during their initial folding and after they have reached their mature state. It has been hypothesized that the strength of this interaction is dictated in large part by differences in the thermal and conformational stabilities of the client protein ([@bib45]). From insights provided by the Hsp90-Cdc37-CDK4 structure, it has been hypothesized that these differences in stability manifest themselves as a differential propensity of kinase domains to adopt an open state in which the N- and C-terminal lobes are separated and can make alternative interactions with Cdc37 and Hsp90 ([@bib47]). Indeed, Cdc37 has been proposed to sort client kinases by testing their ability to resist local unfolding ([@bib18]). Although weak client kinases can be hypothesized to be proteins that readily escape Cdc37 because they have an elevated stability, strong clients remain associated with Cdc37-Hsp90 because they are metastable. As a result, they are held in a protected state until relinquished to an appropriate partner. Such a model would explain the observed ability of the Cdc37-Hsp90 complex, through Cdc37, to both recognize diverse protein kinase sequences with widely different affinities and to sequester them until an appropriate binding partner is available ([@bib7], [@bib18], [@bib47]).

Members of the cyclin-dependent protein kinase (CDK) family differ substantially in their dependency on the Cdc37-Hsp90 pathway ([@bib45]). CDKs that regulate the cell cycle all require cyclin binding for full activity ([@bib26]). Given the expression profiles of their cognate cyclins, the cell cycle CDKs, CDKs 1, 2, 4, and 6, may exist during some stages of the cell cycle in a non-cyclin-bound inactive state. Indeed, early studies to purify CDK complexes identified monomeric CDK1 and CDK2 in cell extracts ([@bib1], [@bib13]). In contrast, many CDK4 partner proteins function in pathways that regulate protein folding and complex assembly, suggesting that CDK4 may not be stable as a monomer ([@bib16]). Consistent with these observations, CDK1 and CDK2 have no dependency on Cdc37-Hsp90, whereas CDK4 and CDK6 are acknowledged Cdc37-Hsp90 client proteins ([@bib22], [@bib28], [@bib39], [@bib42], [@bib45]). These observations suggest that monomeric CDK1 and CDK2 are relatively stable in the absence of their cognate binding partners but that CDK4 and CDK6 distribute into larger complexes that can include Cdc37 and Hsp90.

Cell cycle CDK-cyclin complexes are regulated by association with members of two families of CDK inhibitors (CKIs) ([@bib15]). The CIP/KIP family binds to both the cyclin and CDK subunits to inhibit CDKs 1, 2, 4, and 6 ([@bib34]), whereas members of the INK family specifically bind to monomeric CDK4 and CDK6 ([@bib8], [@bib35]). Although the INK and cyclin D binding sites on CDKs do not overlap, INK binding alters the relative disposition of the N- and C-terminal lobes of the CDK4 or CDK6 kinase domain and, thus, through allostery, weakens the CDK interaction with its cyclin partner ([@bib8], [@bib35]). In apparent contradiction to their role as CDK inhibitors, members of the CIP/KIP family have also been described as assembly factors that promote the formation of CDK4/6-cyclin D complexes during G1 (([@bib5], [@bib6], [@bib10], [@bib21], [@bib41], [@bib49]; reviewed in [@bib37]), and, dependent on the state of CKI phosphorylation, ternary CDK-cyclin-CKI complexes can be catalytically active ([@bib23], [@bib32]). This activity is also proposed to promote G1 progression by sequestering CIP/KIP CKIs to create an environment in which the activity of CDK2 can rise, driven by increasing cyclin E expression ([@bib38]). Taken together, previous studies suggest that the relative importance of these apparently contradictory CKI roles in regulating cell cycle progression are dependent on cell type and prevailing conditions.

The molecular details of how any client kinase is relinquished by Cdc37-Hsp90 have not been elaborated. Cdc37-Hsp90 association with CDK4 *in vivo* is mutually exclusive with either cyclin ([@bib42]) or p16INK4a ([@bib22]) binding, suggesting that either protein might be a suitable partner to which Cdc37-Hsp90 would transfer its client. In this study, we set out to characterize the interactions of CDK4 and CDK6 with the Cdc37-Hsp90 chaperone pathway and to determine whether known CDK binding proteins can displace CDK4 or CDK6 from Cdc37-Hsp90 complexes. We demonstrate in cell-free assays that CDK4 and CDK6 can both interact with Cdc37 and Cdc37-Hsp90 but differ considerably in their affinities. CDK6 is a relatively weak client and can readily be displaced from Cdc37 by members of the INK family or D-type cyclins. CDK4, in contrast, is a strong client and binds tightly to Cdc37 and to Cdc37-Hsp90. We show that Cdc37-Hsp90 will relinquish CDK4 to members of the INK family but not to D-type cyclins. We find that cancer-associated p16INK4a mutations differ in their modes of action toward CDK4 and CDK6 and in their abilities to displace CDK4 and CDK6 from Cdc37. The CKIs p21CIP1 and p27KIP1 cooperate with the D-type cyclins to generate CDK4/6-containing ternary complexes that are resistant to cyclin D displacement by Cdc37, suggesting a molecular mechanism for CIP/KIP assembly factor activity. Our results demonstrate that CDK4 and CDK6 are distinguished as clients of the Cdc37/Hsp90 system by cyclin and INK partners.

Results {#sec2}
=======

Monomeric CDKs Exhibit Differing Affinities for Cdc37 {#sec2.1}
-----------------------------------------------------

To evaluate whether the pattern of dependency on Cdc37-Hsp90 that is observed in cells can be recapitulated with purified proteins, CDKs 2, 4, and 6 were tested for their ability to bind to Cdc37 *in vitro*. Using a homogeneous time-resolved fluorescence (HTRF) assay ([Figure 1](#fig1){ref-type="fig"}A), the measured affinities of CDK4 and CDK6 for Cdc37 were approximately 90 nM and greater than 500 nM respectively, whereas no interaction could be detected between Cdc37 and CDK2 ([Figure 1](#fig1){ref-type="fig"}B; [Table 1](#tbl1){ref-type="table"}; [Figure S1](#mmc1){ref-type="supplementary-material"}). The interactions were also tested using surface plasmon resonance (SPR) immobilizing GSTCDK4 or GSTCDK6, and similar affinities were measured ([Figures S1](#mmc1){ref-type="supplementary-material"}C and [1](#fig1){ref-type="fig"}D). These affinities are comparable with the value of approximately 200 nM reported for the Cdc37-B-Raf^V600E^ kinase domain interaction, measured by isothermal titration calorimetry ([@bib30]), and reinforce the idea that stable interaction with Cdc37 is the primary determinant of whether a kinase is an Hsp90 client. As previously reported, CDK4 and CDK6 can be distinguished by their affinities for Cdc37 ([@bib42], [@bib45]). We next set out to determine how known CDK4/6 regulators might affect the interactions between CDK4 and CDK6 with Cdc37.Figure 1CDK4 and CDK6 Bind to Cdc37(A) Homogeneous time-resolved fluorescence (HTRF) assay format.(B) Cdc37 binding to CDK4 (blue line) and to CDK6 (red line) measured by HTRF. The concentration of CDK4 and CDK6 used in these assays was 10 nM. From SPR titrations between GSTCDK4 or GSTCDK6 and Cdc37, it can be calculated that 34% and 20%, respectively, of the CDK4 and CDK6 are active ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D).(C and D) ATP-competitive inhibitors can displace Cdc37 from a CDK4-Cdc37 (C) or CDK6-Cdc37 (D) complex. CDK4 and CDK6 concentrations were 8 nM and 6 nM, respectively. HTRF measurements were carried out in duplicate and repeated on 3 separate days. The error bars indicate SD.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.Table 1Dissociation Constants for the Binding of Cdc37 and Cyclins to CDK4 or CDK6CDK4CDK6Cdc3792 ± 29460 ± 230[a](#tblfn1){ref-type="table-fn"}Vcyclin151 ± 1114.9 ± 8.8Kcyclin24.9 ± 9.110.0 ± 3.5[^4][^5]

ATP-Competitive Inhibitors Antagonize the Interaction between CDK4 or CDK6 and Cdc37 {#sec2.2}
------------------------------------------------------------------------------------

A general model has been proposed for the action of protein kinase ATP-competitive inhibitors as agents that antagonize the Cdc37-client protein kinase interaction, depriving the client of access to the Hsp90 chaperone system and, thereby, promoting its ubiquitylation and proteasomal degradation ([@bib30]). To test whether this model extends to CDK4 and CDK6, we adapted the HTRF assay to run in a competition format. ATP and three potent CDK4/6 inhibitors, PD0332991 (palbociclib), LEE011, (ribociclib), and LY2835219 (abemaciclib), with measured half-maximal inhibitory concentration (IC~50~) values against CDK4/6-cyclin D of 11/15 nM, 10/39 nM, and 2/5 nM, respectively (values compiled in [@bib38]) were titrated into pre-formed CDK4- or CDK6-Cdc37 complexes ([Figures 1](#fig1){ref-type="fig"}C and 1D). All three inhibitors were able to displace Cdc37 from CDK partners. PD0332991 is more potent than LEE011 at displacing CDK4 and CDK6 from Cdc37, and against CDK6, LY2835219 is as effective as PD0332991. CDK6 was more readily displaced from Cdc37 than CDK4 by PD0332991 and LEE011. ATP was unable to displace Cdc37 at physiological (millimolar) concentrations ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F). Despite repeated attempts, we were unable to derive reproducible inhibition curves for the activity of LY2835219 toward CDK4-Cdc37. This result suggests that the binding of LY2835219 to CDK4 is not described by a straightforward reversible 1:1 interaction under our assay conditions or may interfere with the assay. Taken together, these results support a model in which Cdc37 and ATP-competitive inhibitor binding to CDK4 or CDK6 are mutually exclusive and suggest that CDK4/6-selective inhibitors also exert at least part of their therapeutic effects through depriving CDK4/6 of access to the Cdc37-Hsp90 system.

Cyclins Distinguish CDKs as Clients of the Cdc37/Hsp90 System {#sec2.3}
-------------------------------------------------------------

Cdc37 and cyclin D binding to CDK4 is mutually exclusive *in cellulo* ([@bib22], [@bib42]), suggesting that D-type cyclins could be suitable partners to which the Cdc37-Hsp90 complex would hand over its client CDK. Unfortunately, recombinant monomeric cyclin D is unstable and prone to aggregation, so we were first obliged to use viral D-type cyclins from Herpesvirus saimiri and Kaposi's sarcoma-associated herpesvirus (referred to as Vcyclin and Kcyclin, respectively) as surrogates. These viral cyclins bind to CDK4 and CDK6 to promote their activity through G1 following viral infection ([@bib24], [@bib44]). The crystal structure of CDK6-Vcyclin shows that cyclin engagement activates the CDK6 to form a heterodimer whose overall organization is reminiscent of activated CDK2-cyclin A ([@bib36]). However, the viral cyclin is distinguished from cyclin D by the absence of a cyclin recruitment site that binds to the RXL recruitment motif that assists binding of various substrates and CIP/KIP inhibitors ([@bib36], [@bib44]).

Using HTRF ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2D) and SPR ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F), both viral cyclins bind to CDK4 and to CDK6, albeit with a slightly lower affinity for CDK4 ([Table 1](#tbl1){ref-type="table"}). To test whether the viral cyclins can displace Cdc37 from a CDK-Cdc37 complex, glutathione S-transferase (GST)-tagged CDK4 or CDK6 was first incubated with biotinylated C-terminally Avi-tagged Cdc37 and then titrated against increasing concentrations of unlabeled Vcyclin or Kcyclin. Both viral cyclins were only just able to completely dissociate a complex of CDK4-Cdc37 at the highest concentration assayed (1 μM; [Figure 2](#fig2){ref-type="fig"}A) but could relatively readily displace CDK6 from a CDK6-Cdc37 complex (100% inhibition achieved at concentrations around 100 nM; [Figure 2](#fig2){ref-type="fig"}B). Our results demonstrate that the viral cyclins can distinguish Cdc37-CDK4 and Cdc37-CDK6 complexes and confirm that Cdc37 and cyclin binding to CDK4/6 is mutually exclusive.Figure 2Cyclin and Cdc37 Binding to CDKs Are Mutually Exclusive(A and B) Kcyclin (red) and Vcyclin (blue) readily displace Cdc37 from CDK6 (B) but not from CDK4 (A). The concentrations of CDK4- and CDK6-containing cyclin D complexes used in the assays were 8 nM (CDK4) and 6 nM (CDK6), respectively. HTRF measurements were carried out in duplicate and repeated on 3 separate days. The error bars indicate SD.(C and D) FLAG-tagged Cdc37 was co-incubated with CDK4-cyclin D1/D3 (C) or CDK6-cyclin D1/D3 (D) and then analyzed by SDS-PAGE and subsequent InstantBlue staining. The upper band present in the CDK6-cyclin samples is CDK6, whereas the lower band is the cyclin D. The upper band of the CDK4-cyclin D1 complex is cyclin D1, whereas the lower band is CDK4. CDK4 and cyclin D3 have very similar masses and, when analyzed together, are not resolved. Inputs are marked by the black bars above the right hand side lanes. CDK4, but not cyclin D1 or D3, is detected bound to the FLAG-tagged Cdc37 beads (C), indicating that Cdc37 has displaced CDK4 from either cyclin partner. In contrast, CDK6 is not detectable bound to Cdc37 when bound to cyclin D3 but is displaced from cyclin D1 following incubation with Cdc37 (D).(E and F) Kcyclin binds to CDK4 (E) and CDK6 (F) and is able to displace CDK6 (F) but not CDK4 (E) from CDK-Cdc37 and CDK-Cdc37-Hsp90β complexes assembled in insect cells. The uncropped gels that include the control lanes to confirm that CDK4, CDK6, Cdc37, and Hsp90 do not stick non-specifically to Avi-tagged beads are included as [Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H. Inputs are marked by the black bars above the right hand side lanes. Samples were analyzed by SDS-PAGE and subsequent InstantBlue staining.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

We next tested whether, as would be predicted by the above results and an equilibrium binding model, authentic D-type cyclins relinquish CDK4 but not CDK6 when challenged with increasing concentrations of Cdc37. FLAG-tagged Cdc37 was bound to beads, incubated with either CDK4-cyclin D1 or D3 or CDK6-cyclin D1 or D3, and then the bound fractions were analyzed by SDS-PAGE ([Figure 2](#fig2){ref-type="fig"}). Under these conditions, CDK4 binds to the Cdc37 beads, and cyclin D1 and cyclin D3 cannot be detected in the pull-down complexes ([Figure 2](#fig2){ref-type="fig"}C). This result suggests that the CDK4-cyclin D1/D3 complexes undergo substantial reversible disassociation, allowing the CDK4 to redistribute into a complex with Cdc37. As would be predicted from the behavior of CDK6 toward the viral cyclins, the CDK6-cyclin D3 complex was stable, and CDK6 binding to Cdc37 was not detectable ([Figure 2](#fig2){ref-type="fig"}D). However, the CDK6-cyclin D1 complex showed a different pattern of activity: it resembles CDK4-cyclin D1/D3 and undergoes detectable dissociation, resulting in the formation of a CDK6-Cdc37 complex. Taken together, these results show that cyclin D1 and cyclin D3 can be distinguished by their respective activities in dissociating Cdc37-CDK4 and Cdc37-CDK6 complexes.

We next sought to determine to what extent the presence of Hsp90β affects the ability of a cyclin partner to disrupt the association of CDK4 and CDK6 with Cdc37. We assembled complexes of CDK4 and CDK6 with Cdc37-Hsp90β in cells by transfecting *Spodoptera frugiperda* (insect) cells with GSTCDK4 or GSTCDK6 and untagged Cdc37~(1--348)~. This strategy permits the co-purification of GSTCDK-Cdc37 and GSTCDK-Cdc37-Hsp90 complexes that incorporate the insect cell Hsp90 in stoichiometric amounts ([@bib46]). The high degree of sequence similarity (\>70%) between human and *S. frugiperda* Hsp90 (SfHsp90) supports a model in which the insect protein makes authentic interactions with the human CDK and Cdc37 proteins. Both binary and ternary complexes were purified by first exploiting the GST tag and then by a subsequent size-exclusion chromatography step ([Figures 2](#fig2){ref-type="fig"}E and 2F, input lanes). These GSTCDK-Cdc37 and GSTCDK-Cdc37-SfHsp90 complexes were then characterized in a pull-down assay using Avi-tagged D-type cyclins as the bait protein. The patterns of CDK4 and CDK6 behavior bound to Cdc37 or to Cdc37-SfHsp90 are similar in this pull-down assay. Kcyclin could extract CDK6 from CDK6-Cdc37 and CDK6-Cdc37-SfHsp90 ([Figure 2](#fig2){ref-type="fig"}F). The binary and ternary CDK4 complexes were refractory to disruption ([Figure 2](#fig2){ref-type="fig"}E). To confirm that the CDK6-Kcyclin complex that was generated following viral cyclin capture of the CDK6 was authentic, its kinase activity was tested using retinoblastoma protein (Rb) as a substrate ([Figure S2](#mmc1){ref-type="supplementary-material"}I). CDK6-Kcyclin displayed robust activity toward Rb, as measured by phosphorylation of S780.

Taken together, these results demonstrate that cyclins can distinguish CDKs as clients of the Cdc37/Hsp90 system. They suggest that cyclin D1 and cyclin D3 have more comparable affinities for CDK4 than CDK6 and that cyclin D3 binds more tightly to CDK6 than cyclin D1. The ability of cyclins to displace their cognate CDKs from Cdc37 can be understood in terms of the relative affinities of each CDK for Cdc37 and cyclin partners. This model predicts that, in a cellular context, the efficiency of CDK4 and CDK6 displacement from Cdc37 will depend on the identity and concentration of the competing cyclin.

CKIs Also Distinguish CDKs as Clients of the Cdc37/Hsp90 System {#sec2.4}
---------------------------------------------------------------

Members of the CIP/KIP and INK families of CKIs also bind to CDKs and might also be partners to which the Cdc37 would hand over the CDK. Using the HTRF assay, we determined that CDK4 and CDK6 bind tightly to p16INK4a, with K~d~ values in the low nanomolar range. However, because these dissociation constants correspond to less than the concentration of bait (GSTCDK) used in the HTRF assay, they represent upper estimates for the affinity of each interaction. To determine more accurate K~d~ values, we re-evaluated the interactions by SPR ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B; [Table 2](#tbl2){ref-type="table"}). In these experiments, GSTCDK4 or GSTCDK6 was captured on the chip, and untagged p16INK4a was flowed over as the ligand. The accuracy of the K~d~ values determined by fitting the kinetic curves (k~on~, k~off~) are compromised by the accuracy with which k~off~ can be determined. However, they do indicate very tight association with calculated K~d~ values of 0.87 ± 0.42 nM and 0.26 ± 0.16, respectively, for the CDK4- and CDK6-p16INK4a interactions.Table 2Characterization of p16INK4a and p16INK4a MutantsCDK4 (K~d~, nM)CDK6 (K~d~, nM)T~m~ (°C)ΔT~m~ (versus p16INK4a) (°C)p16INK4a0.87 ± 0.420.26 ± 0.1647.5 (±1.9)0.0p16D84NND59.7 ± 12.045.1 (±1.9)−1.8 (±0.10)p16D108N2.56 ± 0.490.28 ± 0.1036.4 (±3.1)−10.5 (±1.29)p16M53IND0.73 ± 0.1542.7 (±0.47)−4.9 (±2.33)p16M53END1.56 ± 0.1943.2 (±0.38)−4.6 (±1.66)[^6]

We then assayed the abilities of the four authentic INK proteins to displace Cdc37 from CDK4- or CDK6-Cdc37 complexes. Addition of increasing concentrations of each authentic INK to CDK4-Cdc37 ([Figure 3](#fig3){ref-type="fig"}A) or CDK6-Cdc37 ([Figure 3](#fig3){ref-type="fig"}B) resulted in a loss of fluorescent signal, demonstrating that INK and Cdc37 binding to CDK4 and CDK6 is mutually exclusive. In this assay, the determination of the K~d~ values is again limited by the component concentrations so that, in each case, the ability of the authentic INK to displace Cdc37 from a CDK-Cdc37 complex can be given an upper value of approximately 8 or 6 nM, respectively (which is the concentration of the GSTCDK4 or GSTCDK6 component used in the assay). To confirm the activity of p16INK4a toward the CDK4/6-Cdc37 interaction in the context of a complex with Hsp90, the GSTCDK-Cdc37 and GSTCDK-Cdc37-SfHsp90 complexes purified from insect cells were characterized in a pull-down assay using Avi-tagged p16INK4a as the bait protein. Confirming the earlier results, Avi-tagged p16INK4a was able to displace both CDK4 and CDK6 from complexes containing Cdc37 and Cdc37-SfHsp90 ([Figures 3](#fig3){ref-type="fig"}C and 3D).Figure 3CKI-Mediated Displacement of Cdc37 from CDK4-Cdc37 and CDK6-Cdc37 Complexes(A and B) Displacement of Cdc37 from CDK4 (A) or CDK6 (B) by members of the INK family.(C and D) p16INK4a is able to displace CDK4 (C) and CDK6 (D) from CDK-Cdc37 and CDK-Cdc37-Hsp90β complexes assembled in insect cells. The uncropped gels that include the control lanes to confirm that CDK4, CDK6, Cdc37, and Hsp90 do not stick non-specifically to Avi-tagged beads are included as [Figure S4](#mmc1){ref-type="supplementary-material"}.(E and F) Mutant p16INK4a varies in its ability to displace Cdc37 from a CDK4-Cdc37 complex (E) or a CDK6-Cdc37 complex (F). The concentrations of CDK4 and CDK6 were 8 nM and 6 nM, respectively.The HTRF measurements presented in (A) and (B) were carried out in duplicate and repeated on 3 separate days. The measurements presented in (C) and (D) were carried out in duplicate and independently repeated twice. The error bars indicate SD. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

Mutant forms of p16INK4a are associated with cancer susceptibility (see <http://www.tumorportal.org>) and would be predicted to have reduced affinity for CDK4 or CDK6. We reviewed the missense *CDKN2A* sequences compiled at <http://www.tumorportal.org> and selected the following p16INK4a residues for further study: M53, D84, and D108. These residues are frequently mutated, and, as inferred by inspection of the crystal structure of CDK6-p16INK4a, they would be predicted to interfere with the p16INK4a-CDK interaction ([@bib8]). Indeed, p16D84N, in which D84 is mutated to an asparagine ([@bib33]), and p16M53I, in which M53 is mutated to an isoleucine ([@bib14]), have been reported to show reduced binding to CDK4 and to CDK6.

We first confirmed this activity for p16D84N. SPR allowed a direct quantitative comparison and highlights the rapid dissociation rate that is an acquired characteristic of this mutant, leading to a significant reduction in its binding to both CDK4 (binding could be detected but not quantified) and CDK6 (K~d~, 60 nM) ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D; [Table 2](#tbl2){ref-type="table"}). Loss of this aspartate side chain removes a key hydrogen bond to R31 of CDK6 or R24 of CDK4, a residue that is also mutated in several cancer types ([@bib40]; <http://www.tumorportal.org>).

Differences in the affinity of p16M53I toward CDK4 and CDK6 are also apparent ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F; [Table 2](#tbl2){ref-type="table"}). Binding of the p16M53I mutant to CDK4 and CDK6, measured by SPR, had k~on~ values comparable with those of wild-type p16INK4a, whereas the dissociation rates of the mutant protein complexes differed markedly from those of wild-type p16 and depended also on the identity of the CDK. Compared with wild-type p16INK4a ([Figure S3](#mmc1){ref-type="supplementary-material"}B), p16M53I showed an approximately 10-fold higher rate of dissociation from CDK6 ([Figure S3](#mmc1){ref-type="supplementary-material"}F), and its dissociation from CDK4 was substantially increased ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Taking the SPR results together, the p16M53I mutant has a similar affinity for CDK6 (K~d~ 0.73 ± 0.15 nM) as p16INK4a (K~d~ 0.26 ± 0.16 nM) but a much reduced affinity for CDK4 (binding could be detected but not quantified; [Table 2](#tbl2){ref-type="table"}). A p16M53E mutant was also assayed by SPR ([Figures S3](#mmc1){ref-type="supplementary-material"}G and S3H; [Table 2](#tbl2){ref-type="table"}) and showed equivalent behavior. Methionine 53 lies at the INK-CDK6 interface, where its side chain points into the CDK6 active site toward a conserved aspartate (CDK6 D104, CDK4 D99) that sits below the ribose hydroxyls of ATP (PDB: [1BI7](pdb:1BI7){#intref0025}, [@bib35]; 1BI8, [@bib8]).

In contrast, the activity of p16D108N (D108 mutated to an asparagine) was very similar to that of p16INK4a ([Figures S3](#mmc1){ref-type="supplementary-material"}I and S3J; [Table 2](#tbl2){ref-type="table"}). Based on these results, we hypothesized that reduced protein stability might mediate this mutant's effects. To test this hypothesis, we used differential scanning fluorimetry (DSF) to determine the melting temperature ™ values for each of the p16INK4a species ([Table 2](#tbl2){ref-type="table"}). Authentic p16INK4a is a stable protein (T~m~ 47.5°C ± 1.9°C), and the introduction of mutations M53I and D84N resulted in small destabilizations (T~m~ values of 42.7°C ± 0.47°C and 45.1°C ± 1.9°C, respectively). However, DSF reveals that the p16D108N mutant is distinguished by its significantly depressed melting temperature (T~m~ value of 36.4°C ± 3.1°C) relative to p16INK4a. This result suggests that this mutation destabilizes p16INK4a, leading to reduced levels of expression rather than inhibiting the interaction with CDK4 or CDK6.

Presuming an equilibrium binding model, a hypothesis that can be proposed from our results is that p16INK4a mutants will differ in their abilities to displace Cdc37 from CDK4 and CDK6. To test this hypothesis, we assayed the p16INK4a mutants in the HTRF displacement assay ([Figures 3](#fig3){ref-type="fig"}E and 3F). p16D84N and p16D108N behaved as expected: p16D84N was unable to displace CDK4 or CDK6 from Cdc37 ([Figures 3](#fig3){ref-type="fig"}E and 3F, gray curves), whereas p16D108N was as effective as wild-type p16INK4a in displacing CDK6 ([Figure 3](#fig3){ref-type="fig"}F, blue curve) and showed only a modest reduction in activity toward CDK4 ([Figure 3](#fig3){ref-type="fig"}E, blue curve). In agreement with our hypothesis, p16M53I is as effective as authentic p16INK4a at displacing Cdc37 from CDK6 ([Figure 3](#fig3){ref-type="fig"}F, cyan curve) but is ineffective at displacing Cdc37 from CDK4 ([Figure 3](#fig3){ref-type="fig"}E, cyan curve).

Taken together, these results suggest that not all p16INK4a mutations detected in tumor cells act through the same mechanism. The observation that p16M53I is as effective at binding to CDK6 as the authentic p16INK4a sequence suggests that this mutation may only be effective in settings where cell cycle progression is driven by CDK4. Furthermore, it can be hypothesized that clinically significant changes to the p16INK4a sequence might not only affect the regulation of CDK4 and CDK6 activity by affecting the direct binding of p16INK4a but also by affecting the ability of p16INK4a to inhibit the interactions of CDK4 and CDK6 with their regulators.

CDK-Cyclin D Complexes Selectively Resist Disruption by Cdc37 in the Presence of p21CIP1 or p27KIP1 {#sec2.5}
---------------------------------------------------------------------------------------------------

Members of the CIP/KIP family have been proposed to act as assembly factors for CDK4/6-cyclin D complexes during G1. As demonstrated above, D-type cyclin alone is unable to displace Cdc37 from CDK4, and CDK4 bound to cyclin D1 or D3 or CDK6 bound to cyclin D1 redistribute into complexes containing Cdc37. From these results, we hypothesized that addition of p21CIP1 or p27KIP1 might stabilize CDK4/6-cyclin D complexes relative to Cdc37 or Cdc37-Hsp90 complexes with CDK4 or CDK6.

Using the HTRF assay, we first observed that full-length p27KIP1 (p27FL) displaced Cdc37 from CDK4-Cdc37 or CDK6-Cdc37, albeit significantly less efficiently than the INKs ([Figures 4](#fig4){ref-type="fig"}A and 4B). The crystal structure of a CDK2-cyclin A-p27KIP1 complex reveals that the N-terminal sequence of p27KIP1 has a significant interaction with the CDK N-terminal lobe that might explain this activity ([@bib34]). Accordingly, constructs related to the co-crystallized fragment of p27KIP1 (residues 1--106, termed p27M) and to that part of the construct that was resolved in the electron density of that complex (p27KIP1 residues 23--106, termed p27S) were assayed for their ability to displace Cdc37 from CDKs 4 and 6. We also assayed corresponding fragments of p21CIP1 (p21M/S, residues 1/9--87). Each of these constructs retains the ability to displace Cdc37 ([Figures 4](#fig4){ref-type="fig"}A and 4B), suggesting that Cdc37 displacement activity resides in residues contained within the "S" fragment constructs of CIP/KIP proteins. However, p27FL was the most potent p27KIP1 construct tested and showed equivalent activity toward CDK4 and CDK6, suggesting that additional p27KIP1 residues C-terminal to residue 106 may contribute to Cdc37 displacement.Figure 4p21CIP1 and p27KIP1 Cooperate with Cyclin D to Prevent Cdc37 Association with CDK4 and CDK6(A and B) p27KIP1~FL~ (p27FL), p21CIP1~S/M~ (p21S, p21M), and p27KIP1~S/M~ (p27S, p27M) can displace CDK4 (A) or CDK6 (B) from Cdc37.(C and D) Cdc37 binds to CDK4 (C) or CDK6 (D) (blue curves) and can effectively displace cyclin D1 (red curves). Upon addition of excess Cdc37, the ternary CDK-cyclin D1-p27KIP1~M~ complexes do not redistribute to form CDK-Cdc37 (green curves).(E) Cdc37 binds to CDK4 (blue) and can effectively displace cyclin D3 bound to CDK4 (red). Upon addition of excess Cdc37, ternary complexes of CDK4-cyclin D3-p27KIP1~M~ or p21CIP1~M~ do not redistribute to form CDK4-Cdc37 (green and magenta curves, respectively).(F) In contrast, CDK6 binds to Cdc37 (blue curve) but cannot be displaced from cyclin D3 by Cdc37 (red curve).All HTRF measurements were carried out in duplicate and repeated. The error bars indicate SD.

To find out whether the CIP/KIP CKIs can cooperate with cyclin D isoforms to generate a stable ternary CDK4 complex that is resistant to displacement by Cdc37, we next purified GSTCDK4-cyclin D1 and D3 and GSTCDK6-cyclin D1 and D3 complexes assembled in insect cells, incubated them with excess p21M or p27M, and isolated the complexes by size-exclusion chromatography. We then used the HTRF assay to measure the association of Avi-tagged Cdc37 with GSTCDK4 and GSTCDK6, which were presented unpartnered, in a binary complex with cyclin D1 or cyclin D3, or in a ternary complex with cyclin D1 or D3 and p21M, or p27M. As shown previously, Cdc37 binds to monomeric CDK4 ([Figures 4](#fig4){ref-type="fig"}C and 4E, blue lines) and effectively displaces cyclin D1 or cyclin D3 ([Figures 4](#fig4){ref-type="fig"}C and 4E, red lines). However, addition of p21M or p27M to CDK4-cyclin D3 ([Figure 4](#fig4){ref-type="fig"}E, magenta and green lines, respectively) or addition of p27M to CDK4-cyclin D1 ([Figure 4](#fig4){ref-type="fig"}C, green line) prevent Cdc37 from binding, suggesting that cyclin D isoforms and the CIP/KIP CKIs cooperate to generate a stable ternary CDK4 complex that is resistant to displacement by Cdc37.

As demonstrated above, Cdc37 binds to free CDK6 ([Figures 4](#fig4){ref-type="fig"}D and 4F, blue lines) and, as expected, was less effective at extracting CDK6 from complexes with cyclin D3 ([Figure 4](#fig4){ref-type="fig"}F, red line). CDK6-cyclin D3-p27M was refractory to disruption ([Figure 4](#fig4){ref-type="fig"}F, green line). Again, cyclin D1 and D3 are distinguished: cyclin D1, unlike cyclin D3 and the viral D-type cyclins, forms a complex with CDK6 that is disrupted by Cdc37 ([Figure 4](#fig4){ref-type="fig"}D, red line). Addition of p27M can stabilize it ([Figure 4](#fig4){ref-type="fig"}D, green line). These results suggest that activation of CDK4 and CDK6 by D-type cyclins can be distinguished by their requirement for the assembly function of p21CIP1 or p27KIP1. We hypothesize that the CIP/KIP proteins assist CDK4 and CDK6 to re-distribute from Cdc37 complexes into stable complexes with cyclin D1. Formation of complexes of CDK6 with cyclin D3 and the viral D-type cyclins, by contrast, are less dependent on this mechanism.

Discussion {#sec3}
==========

Protein kinases differ in their apparent affinity for Cdc37, and it has been hypothesized that the strength of this interaction reflects the inherent stability of the client kinase fold ([@bib45]) ([@bib18]). However, the simple reversibility of the interaction with Cdc37 *in vitro* and the ability of this interaction to be inhibited by small-molecule ATP-competitive kinase inhibitors ([@bib30]) strongly suggest that recruitment to the Cdc37-Hsp90 system is more about regulation than protein folding ([@bib18], [@bib47]). Client kinases recruited to Cdc37-Hsp90 complexes are thought to undergo repeated cycles of release and recapture driven by the Hsp90 ATPase-coupled chaperone cycle until they escape the cycle through achieving an active state and/or by finding an appropriate partner ([@bib31]). Alternatively, when the chaperone ATPase cycle is blocked, the kinase becomes ubiquitylated and subsequently degraded by the proteasome ([@bib9], [@bib20], [@bib27]). We have shown that ATP-competitive drugs targeting CDK4/6 have a shared mechanism of action with small-molecule inhibitors of other Hsp90-dependent kinases ([@bib30]) and block Cdc37 binding to deprive CDK4 and CDK6 of access to the Hsp90 chaperone system. It is yet to be determined whether enhanced CDK4/6 degradation through the proteasome system may also be an unintended but therapeutically valuable consequence of the action of CDK4/6 inhibitors or whether alternative dysregulated pathways emerge ([@bib29], [@bib30]).

The central hypothesis of this paper is that much of the behavior of CDK4/6 in respect of their interactions with Cdc37-Hsp90 can be explained by thermodynamic partitioning between chaperoned (in complex with Cdc37 with or without Hsp90), activated (in complex with cyclins), and inhibited (in complex with INK) complexes ([Figure 5](#fig5){ref-type="fig"}). CDK4 and CDK6 can reversibly associate with Cdc37 in a state that is poised for displacement by CDK regulators. The recently published structure of a CDK4-Cdc37-Hsp90 complex supports this model and reveals, at least for CDK4, that the poised state is one in which the kinase is considerably unfolded ([@bib47]). As a prediction of this structural model, it was proposed that rising cyclin D concentrations could provide sufficient stabilization energy so that unfolded CDK4 would be displaced from Cdc37 to form a folded CDK4-cyclin D complex. Our results extend this model to show that CDK4 and CDK6 are distinguished as Cdc37 clients by their differing affinities and that differences in the affinities of CDK regulators (INKs versus cyclin D1 versus cyclin D3) for CDK4 and CDK6 have the potential to affect CDK4 and CDK6 displacement from Cdc37 to create a network of finely tuned signaling interactions to regulate CDK4 and CDK6 activity.Figure 5Exchange of CDKs into and out of Complexes Containing Cdc37The experiments reconstitute the redistribution of CDKs 4 and 6 (blue) between complexes that contain Cdc37 (coral) and complexes that contain other binding partners drawn from ATP-competitive inhibitors (red), cyclins (green), CIP/KIP family CKIs (yellow), and INK family CKIs (purple). Boxed half arrows indicate the half reactions of these equilibria that have been reconstituted in the present study. Smaller arrows in the "reverse" direction (i.e., toward complexes that contain Cdc37) indicate reactions where the competitor appears to bind to CDKs substantially more tightly than does Cdc37. Partitioning between the different partnered states is presumed to proceed via unbound states of the kinase, which exist in an equilibrium between less folded "open" states (which preferentially bind to the chaperone system) and more folded "closed" states (which preferentially bind to the other partners).

We demonstrate that the different authentic INK proteins bind tightly to CDK4 and CDK6 and are highly effective at displacing CDK4 or CDK6 from Cdc37-Hsp90β. We also show that clinically relevant INK mutants can be selected in cancer cells that inactivate CDK4 and CDK6 through different mechanisms and, as a result, also show differing abilities to displace Cdc37 bound to CDK4 or CDK6.

The behavior of p16D84N and p16D108N, both as CDK4/6 binding proteins and as partners to which the Cdc37-Hsp90 chaperone system will relinquish their CDK4 or CDK6 clients, can be rationalized, respectively, by their location at the INK-CDK interface (D84N) and effect on INK stability (D108N). p16D84N has previously been reported to inhibit CDK4-cyclin D1 kinase activity as effectively as wild-type p16INK4a and to be modestly less effective at inhibiting G1 progression ([@bib19]). Taken together, these results suggest that p16INK4a mutations can exert their effects by altering the equilibrium distribution of p16INK4a between multiple CDK4- and CDK6-containing complexes.

Mutations to p16INK4a residue M53 showed unexpected behavior, distinguishing CDK4 and CDK6. This mutant is equivalent to wild-type p16INK4a in its affinity for CDK6 but displays an enhanced k~off~ rate toward CDK4, resulting in a \>10^6^-fold reduction in the strength of the interaction. As a result, p16M53I is as effective as authentic p16INK4a in its ability to displace CDK6 from a preformed CDK6-Cdc37 complex but has a much reduced ability to displace CDK4 from Cdc37. These results suggest that the disease-associated activity of this mutant may be manifested primarily through its activity toward CDK4. This behavior has also been reported for another p16INK4a mutant also identified in familial melanoma in which R24 is mutated to a proline ([@bib17]).

Cyclins, however, display a range of efficiencies. As expected, this spectrum of cyclin D activity favors CDK6-cyclin complexes because CDK6 is a weaker Cdc37-Hsp90 client. In the presence of viral cyclins or cyclin D3, CDK6 partitions from a chaperoned into a cyclin-bound complex. In the presence of cyclin D1, however, we observed different behavior. Specifically, we found that CDK6 spontaneously redistributes from cyclin D1 into a CDK6-Cdc37-Hsp90 complex, suggesting that the affinity of cyclin D1 for CDK6 is not sufficient to overcome that of Cdc37-Hsp90. CDK4 however, is a strong Cdc37-Hsp90 client, and as a result, no cyclins tested were able to partition the CDK4 away from Cdc37-Hsp90. These results suggest a fine-tuning of the system to distinguish the affinities of different cyclin D isoforms toward CDK4 and CDK6. This situation changes, however, when the cyclin is partnered by either p21CIP1 or p27KIP1. Although these CKIs are inefficient at displacing Cdc37 from CDK4/6 when alone, when present with either cyclin D1 or cyclin D3, they form a stable ternary complex that is resistant to redistribution of the CDK into a Cdc37-Hsp90 complex. We have provided direct evidence that p27KIP1 can perturb the distribution of CDKs between Cdc37-containing and cyclin-containing complexes in experiments that reconstitute the reverse reaction. Because the results presented in this paper demonstrate that both forward and reverse reactions can occur spontaneously, it is reasonable to infer that inhibition of the reverse reaction is functionally equivalent to promoting the forward reaction, an equilibrium model that is consistent with an analysis of the CDK4-Cdc37-Hsp90 structure ([@bib47]). We hypothesize that this behavior provides a potential molecular mechanism for the well documented activity of p21CIP1 and p27KIP1 as "assembly factors" for CDK4/6-cyclin D-containing complexes during G1.

We propose that other CDK4 and CDK6 regulators may be able to displace both CDK4 and CDK6 from Cdc37. Such a model has been proposed from cell-based studies ([@bib43]). Our in vitro experiments complement this approach and provide a more quantitative assessment of the different molecular interactions involved. The differences we observe in the interplay of CDK4 and CDK6 and their partners with the components of the Hsp90 system could explain the apparently contradictory studies in mouse embryonic fibroblasts (MEFs) that have addressed the roles of CKIs in assembling CDK4 and CDK6 complexes. MEFs lacking p21CIP1 and p27KIP1 have been reported to fail to assemble CDK4/6 complexes ([@bib10]), to assemble them but to a much lower level ([@bib43]), or to assemble them under conditions where cyclin D levels were elevated ([@bib2]). In another study in HCT116 cells, overexpression of Cdc37 suppressed CDK4 binding to p16 but enhanced CDK4 binding to cyclin D ([@bib50]).

Taken together with our results, a unifying model is that the CIP/KIP and INK families of CDK inhibitors may each play a role in CDK4/6-cyclin D assembly. For INKs, this role would be mediated by their ability to compete with cyclins to displace CDKs from Cdc37, whereas for CIP/KIPs, the role would be through assisting cyclin D in sequestering CDKs from Cdc37. It can be hypothesized that CDK4 and CDK6 differ in their requirements for the CKIs to act as assembly factors. Our results support a model in which CDK6 is handed over from Cdc37 to form a relatively stable CDK6-cyclin D3 complex. At the other extreme, the weaker affinity of CDK4 for cyclin D1 or cyclin D3, coupled with the higher affinity of CDK4 for Cdc37, suggests a greater dependency on CKI assembly factor activity and/or a requirement for higher cyclin D concentrations before Cdc37 would hand over this CDK to its activating partner. We note that CDK4/6-cyclin D1 complexes remain relatively unstable, suggesting that they may be susceptible to continued exchange between cyclin and Cdc37 partners unless their subsequent modification acts to stabilize them. Given that cyclin D1 is the most widely expressed cyclin D in different cell types and is most frequently implicated as a cancer driver in solid tumors ([@bib3]), we hypothesize that, in many clinical settings, activation of CDK6 may be enhanced by the assembly function of p21CIP1 or p27KIP1. Our results further suggest that a subset of p16INK4a mutations will be most detrimental in cancer settings driven by CDK4. Finally, we note that other CDK4/6 regulators and /or CDK4/6 phosphorylation may also provide additional stabilization energy to displace CDK4 or CDK6 from Cdc37, providing multiple opportunities for the Cdc37-Hsp90 chaperone system to fine-tune CDK4 and CDK6 activities.

Experimental Procedures {#sec4}
=======================

Protein Expression {#sec4.1}
------------------

Proteins were expressed in recombinant *E. coli* cells or in *Sf*9 insect cells using a recombinant baculovirus expression system ([@bib4]) and purified by sequential affinity and size-exclusion chromatography.

Interaction Assays {#sec4.2}
------------------

Pull-down assays were conducted at 4°C with the target protein present in a 3-fold molar excess to the bait and visualized by SDS-PAGE and subsequent staining with InstantBlue. For HTRF assays, one of the interacting partners was purified as a GST fusion, whereas the other was expressed with an Avi tag to allow subsequent biotinylation. Interactions between the partners gave rise to a fluorescent signal because of developing reagents comprising a turbium-conjugated anti-GST antibody and the fluorescent dye SAXL665 coupled to streptavidin. For competition HTRF assays, binary complexes were established with one partner present in trace concentrations and the other poised at its apparent K~d~. Competitors were titrated across a range of concentrations, and their competitive binding was observed as a loss of fluorescence resonance energy transfer (FRET) signal. For SPR assays, CDK4 and CDK6 were immobilized as GST fusions on a chip via anti-GST antibody coupling and exposed to dilution series of the various ligands. K~d~ values were derived from fitting the binding and dissociation curves to derive k~on~ and k~off~ rates. Data were analyzed either using GraphPad Prism version 6 (GraphPad) (HTRF) or Biacore S200 evaluation software (SPR).

DSF {#sec4.3}
---

Thermal melting experiments to determine T~m~ values for wild-type and mutant p16INK4a proteins were carried out essentially as described previously ([@bib25]).

Detailed protocols for all the methods are provided in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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